Emerging biomarkers in cognition

Meredith Wicklund, Ronald Carl Petersen

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Knowledge of aging and dementia is rapidly evolving with the aim of identifying individuals in the earliest stages of disease processes. Biomarkers allow clinicians to show the presence of a pathologic process and resultant synapse dysfunction and neurodegeneration, even in the earliest stages. This article focuses on biomarkers for mild cognitive impairment caused by Alzheimer disease, structural magnetic resonance imaging, fluorodeoxyglucose positron emission tomography (PET) or single-photon emission computed tomography, and PET with dopamine ligands. Although these biomarkers are useful, several limitations exist. Several new biomarkers are emerging and a more biological characterization of underlying pathophysiologic spectra may become possible.

Original languageEnglish (US)
Pages (from-to)809-828
Number of pages20
JournalClinics in Geriatric Medicine
Volume29
Issue number4
DOIs
StatePublished - Nov 2013

Fingerprint

Cognition
Biomarkers
Positron-Emission Tomography
Pathologic Processes
Single-Photon Emission-Computed Tomography
Synapses
Dementia
Dopamine
Alzheimer Disease
Magnetic Resonance Imaging
Ligands

Keywords

  • Alzheimer disease
  • Biomarkers
  • Dementia

ASJC Scopus subject areas

  • Geriatrics and Gerontology

Cite this

Emerging biomarkers in cognition. / Wicklund, Meredith; Petersen, Ronald Carl.

In: Clinics in Geriatric Medicine, Vol. 29, No. 4, 11.2013, p. 809-828.

Research output: Contribution to journalArticle

Wicklund, Meredith ; Petersen, Ronald Carl. / Emerging biomarkers in cognition. In: Clinics in Geriatric Medicine. 2013 ; Vol. 29, No. 4. pp. 809-828.
@article{ab29ab4b489b479e9dccce00a2a0541b,
title = "Emerging biomarkers in cognition",
abstract = "Knowledge of aging and dementia is rapidly evolving with the aim of identifying individuals in the earliest stages of disease processes. Biomarkers allow clinicians to show the presence of a pathologic process and resultant synapse dysfunction and neurodegeneration, even in the earliest stages. This article focuses on biomarkers for mild cognitive impairment caused by Alzheimer disease, structural magnetic resonance imaging, fluorodeoxyglucose positron emission tomography (PET) or single-photon emission computed tomography, and PET with dopamine ligands. Although these biomarkers are useful, several limitations exist. Several new biomarkers are emerging and a more biological characterization of underlying pathophysiologic spectra may become possible.",
keywords = "Alzheimer disease, Biomarkers, Dementia",
author = "Meredith Wicklund and Petersen, {Ronald Carl}",
year = "2013",
month = "11",
doi = "10.1016/j.cger.2013.07.006",
language = "English (US)",
volume = "29",
pages = "809--828",
journal = "Clinics in Geriatric Medicine",
issn = "0749-0690",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Emerging biomarkers in cognition

AU - Wicklund, Meredith

AU - Petersen, Ronald Carl

PY - 2013/11

Y1 - 2013/11

N2 - Knowledge of aging and dementia is rapidly evolving with the aim of identifying individuals in the earliest stages of disease processes. Biomarkers allow clinicians to show the presence of a pathologic process and resultant synapse dysfunction and neurodegeneration, even in the earliest stages. This article focuses on biomarkers for mild cognitive impairment caused by Alzheimer disease, structural magnetic resonance imaging, fluorodeoxyglucose positron emission tomography (PET) or single-photon emission computed tomography, and PET with dopamine ligands. Although these biomarkers are useful, several limitations exist. Several new biomarkers are emerging and a more biological characterization of underlying pathophysiologic spectra may become possible.

AB - Knowledge of aging and dementia is rapidly evolving with the aim of identifying individuals in the earliest stages of disease processes. Biomarkers allow clinicians to show the presence of a pathologic process and resultant synapse dysfunction and neurodegeneration, even in the earliest stages. This article focuses on biomarkers for mild cognitive impairment caused by Alzheimer disease, structural magnetic resonance imaging, fluorodeoxyglucose positron emission tomography (PET) or single-photon emission computed tomography, and PET with dopamine ligands. Although these biomarkers are useful, several limitations exist. Several new biomarkers are emerging and a more biological characterization of underlying pathophysiologic spectra may become possible.

KW - Alzheimer disease

KW - Biomarkers

KW - Dementia

UR - http://www.scopus.com/inward/record.url?scp=84884789456&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884789456&partnerID=8YFLogxK

U2 - 10.1016/j.cger.2013.07.006

DO - 10.1016/j.cger.2013.07.006

M3 - Article

C2 - 24094298

AN - SCOPUS:84884789456

VL - 29

SP - 809

EP - 828

JO - Clinics in Geriatric Medicine

JF - Clinics in Geriatric Medicine

SN - 0749-0690

IS - 4

ER -